Skip to main content
main-content

Expert opinion

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.


Concise and thought-provoking commentary, opinion, and analysis from leading oncology experts.


IDO inhibitors in advanced melanoma: A path forward?

IDO inhibitors

On the back of success in melanoma with PD-1 and CTLA-4 checkpoint inhibitors, attention has turned to other checkpoint proteins such as indoleamine 2,3-dioxygenase (IDO). In this editorial, Zeynep Eroglu (Moffitt Cancer Center, USA) discusses the advances and setbacks in the development of IDO inhibitors for melanoma.

Immunotherapy for patients with metastatic NSCLC harboring an EGFR mutation

DNA samples

Management of EGFR-mutant non-small-cell lung cancer has been dominated by targeted therapies, but it is less clear where immunotherapy will fit into the treatment paradigm. Charu Aggarwal (University of Pennsylvania, USA) explores the current place of immunotherapy in treating this disease.

Management of EGFR mutation-positive non-small-cell lung cancer: Two steps forward, looking back

Adenocarcinoma histology

Caroline McCoach (Helen Diller Family Comprehensive Cancer Center, CA, USA) and Howard (Jack) West (Swedish Cancer Institute, WA, USA) discuss the way forward after great progress with tyrosine kinase inhibitors targeting the epidermal growth factor receptor in non-small-cell lung cancer.

Developing polygenic risk scores for breast cancer

3D illustration of a method of DNA sequencing

Gareth Evans (University of Manchester, UK) details how genetic advances have allowed the development of relatively cheap and clinically meaningful genetic-based scores for breast cancer risk, further heralding the shift towards precision medicine in breast cancer.

Choosing an immunotherapy approach in patients with advanced NSCLC

Advanced NSCLC

Liza Villaruz (Hillman Cancer Center, PA, USA) examines recent KEYNOTE trials investigating pembrolizumab for advanced non-small-cell lung cancer and the questions they raise regarding patient selection and combination therapy.

Bipolar androgen therapy: Progress and future directions

Bipolar androgen therapy: Progress and future directions

Michael Schweizer (University of Washington, Seattle, USA) outlines a new therapy that utilizes both androgen deprivation and administration, which may potentially have benefit for prostate cancer patients.

Urinary biomarkers in the management of prostate cancer

Urinary biomarkers in the management of prostate cancer

Non-invasive biomarkers have the potential to guide and improve prostate cancer management in many ways. Maria Frantzi, Agnieszka Latosinska, and Harald Mischak (Mosaiques Diagnostics GmbH, Germany) outline some promising markers and what is needed to implement them in the clinic.

Breast cancer-related lymphedema management: Current state and future directions

Lymphedema management

Breast cancer-related lymphedema is a debilitating complication of breast cancer surgery. Babak Mehrara (Memorial Sloan Kettering Cancer Center, NY, USA) outlines the current state of lymphedema management and poses some questions for the future.

Challenges of an aging and increasingly obese breast cancer survivor population: Are we ready?

Obesity and breast cancer

In an aging population with rising obesity levels, comorbidities and worse overall prognoses for breast cancer patients are a growing concern. Damien Hansra (Cancer Treatment Centers of America, GA, USA) calls for more education and preparation to combat this concerning public health threat.

Discontinuing tyrosine kinase inhibitors in chronic myeloid leukemia

Ehab Atallah

Tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) can result in prolonged and deep responses in many patients. In such cases, can TKIs be safely discontinued to avoid adverse side effects and costs? Etab Atallah (Medical College of Wisconsin, USA) discusses the current issues surrounding TKI discontinuation in CML.

02-04-2019 | Advanced breast cancer | Editorial | Article

The use of CDK4/6-inhibitors in advanced, hormone-receptor positive breast cancer: why, when and who?

CDK4/6 inhibitors are a valuable addition to the treatment armamentarium for HR-positive, HER2-negative advanced breast cancer, but questions about their use remain. The research team behind the Dutch Sonia study explores some of the most pressing questions.

28-01-2019 | Melanoma | Editorial | Article

IDO inhibitors in advanced melanoma: A path forward?

On the back of success in melanoma with PD-1 and CTLA-4 checkpoint inhibitors, attention has turned to other checkpoint proteins such as indoleamine 2,3-dioxygenase (IDO). In this editorial, Zeynep Eroglu (Moffitt Cancer Center, USA) discusses the advances and setbacks in the development of IDO inhibitors for melanoma.

06-11-2018 | Immunotherapy | Editorial | Article

Immunotherapy for patients with metastatic NSCLC harboring an EGFR mutation

Management of EGFR-mutant non-small-cell lung cancer has been dominated by targeted therapies, but it is less clear where immunotherapy will fit into the treatment paradigm. Charu Aggarwal (University of Pennsylvania, USA) explores the current place of immunotherapy in treating this disease.

16-08-2018 | Non-small cell lung cancer | Article

Management of EGFR mutation-positive non-small-cell lung cancer: Two steps forward, looking back

Caroline McCoach (Helen Diller Family Comprehensive Cancer Center, CA, USA) and Howard (Jack) West (Swedish Cancer Institute, WA, USA) discuss the way forward after great progress with tyrosine kinase inhibitors targeting the epidermal growth factor receptor in non-small-cell lung cancer.

02-08-2018 | Breast cancer | Editorial | Article

Developing polygenic risk scores for breast cancer

Gareth Evans (University of Manchester, UK) details how genetic advances have allowed the development of relatively cheap and clinically meaningful genetic-based scores for breast cancer risk, further heralding the shift towards precision medicine in breast cancer.

26-07-2018 | Non-small cell lung cancer | Editorial | Article

Choosing an immunotherapy approach in patients with advanced NSCLC

Liza Villaruz (Hillman Cancer Center, PA, USA) examines recent KEYNOTE trials investigating pembrolizumab for advanced non-small-cell lung cancer and the questions they raise regarding patient selection and combination therapy.

06-07-2018 | Prostate cancer | Editorial | Article

Bipolar androgen therapy: Progress and future directions

Michael Schweizer (University of Washington, Seattle, USA) outlines a new therapy that utilizes both androgen deprivation and administration, which may potentially have benefit for prostate cancer patients.

02-07-2018 | Prostate cancer | Editorial | Article

Urinary biomarkers in the management of prostate cancer

Non-invasive biomarkers have the potential to guide and improve prostate cancer management in many ways. Maria Frantzi, Agnieszka Latosinska, and Harald Mischak (Mosaiques Diagnostics GmbH, Germany) outline some promising markers and what is needed to implement them in the clinic.

28-06-2018 | Surgery | Editorial | Article

Breast cancer-related lymphedema management: Current state and future directions

Breast cancer-related lymphedema is a debilitating complication of breast cancer surgery. Babak Mehrara (Memorial Sloan Kettering Cancer Center, NY, USA) outlines the current state of lymphedema management and poses some questions for the future.

01-05-2018 | Obesity | View from the clinic | Article

Body fat and cancer: Why does it matter?

Elevated levels of body fat have consistently been found to be associated with increased risk of a number of cancers. In this 'View from the clinic' article Daniel Nixon (Southeastern Regional Medical Center, USA) explores this relationship and provides his perspective on how to educate and support patients.

Image Credits